K

M

KHATTAK , Muhammad A.

Last name: KHATTAK

First name: Muhammad A.

March 5, 2024 (v1)

Publication

Metadata-only

Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

Khattak, Muhammad A. Luke, Jason J. Long, Georgina V.

Abstract Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. Methods: Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, patients 12 to <18...

Uploaded on: March 7, 2024